AbbVie Inc. is 95.1x more valuable than Dianthus Therapeutics, Inc. /DE/ by market capitalization ($397.44 B vs $4.18 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | DNTH | ABBV |
|---|---|---|
| Market cap | $4.18 B | $397.44 B |
| US-listed rank | #1530 | #28 |
| Revenue (latest FY) | $2.04M | $61.16B |
| Net income (latest FY) | -$162.34M | $4.23B |
| Net margin | -7973.3% | 6.9% |
| P/E (trailing FY) | - | 94.0 |
| SEC filings | 624 | 1,008 |
AbbVie Inc. is 95.1x more valuable than Dianthus Therapeutics, Inc. /DE/ by market capitalization ($397.44 B vs $4.18 B).
In their latest fiscal years, Dianthus Therapeutics, Inc. /DE/ reported $2.04M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Dianthus Therapeutics, Inc. /DE/ and AbbVie Inc., or browse the full rankings.